BioPharmSignal logoBioPharmSignal

Biotech News

Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates

Avalo Therapeutics (AVTX)Avalo TherapeuticsEarnings

AVTX (AVTX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is avtx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

AVTXAvalo Therapeutics2026-05-13 11:00 EST

Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

AVTXAvalo Therapeutics2026-05-05 20:01 EST

Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa

GPCRStructure Therapeutics2026-05-07 20:06 EST

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

SNGXSOLIGENIX2026-05-08 11:30 EST

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

ZURAZura Bio2026-05-07 11:30 EST

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

KYMRKymera2026-04-30 11:00 EST

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

NRIXNurix Therapeutics2026-04-08 10:00 EST

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

ZURAZura Bio2026-03-19 20:05 EST

Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates

IMVTImmunovant2026-05-20 11:00 EST

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

KYMRKymera2026-04-23 11:00 EST

Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026

View all latest news

Avalo Therapeutics

Avalo Therapeutics is a biotechnology company focused on immune-mediated and inflammatory diseases. Its pipeline aims at selective immune pathways and niche inflammation opportunities.

Recent company news

AVTXAvalo Therapeutics2026-07-22 11:00 EST

Avalo Therapeutics to Participate in the BTIG Biotechnology Conference

AVTXAvalo Therapeutics2026-07-07 11:00 EST

Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum

AVTXAvalo Therapeutics2026-06-26 11:00 EST

Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes

AVTXAvalo Therapeutics2026-06-23 11:00 EST

Avalo Therapeutics Appoints Ron Philip to Board of Directors

AVTXAvalo Therapeutics2026-06-16 11:00 EST

Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody

Stock data

Close
19.50 USD
Market cap
733.82M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States